Holen Sie sich die Stockscreener-App
6.05
7.27%
0.41
Vorhandelsmarkt:
5.99
-0.06
-0.99%
Immunitybio Inc Aktie (IBRX) Neueste Nachrichten
New Sign-Off Propels ImmunityBio - Los Angeles Business Journal
ImmunityBio rally causes $492M paper losses for short sellers - MSN
Aug Ideas: Does ImmunityBio Inc have a competitive edgeOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio initiates another cell therapy trial with no chemotherapy needs - MSN
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bath & Body Works, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBWI - GlobeNewswire Inc.
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
BTIG Reaffirms Their Buy Rating on ImmunityBio (IBRX) - The Globe and Mail
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler see label expansion potential for ImmunityBio, Inc. (IBRX)’s Anktiva following Quilt data - MSN
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - Business Wire
ImmunityBio Stock: Commercialization Efforts Accelerate Following Key Approvals - AD HOC NEWS
ImmunityBio shares jump after constructive FDA talks on bladder cancer therapy - MSN
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock - TechStock²
ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run - MSN
Did ANKTIVA’s Expanding Approvals and Chemo‑Free GBM Data Just Shift ImmunityBio’s (IBRX) Investment Narrative? - Sahm
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
Clinical Promise and Regulatory Scrutiny Collide for ImmunityBio - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ImmunityBio Stock Surges on Clinical and Commercial Momentum - AD HOC NEWS
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX - TechStock²
ImmunityBio (NASDAQ:IBRX) Trading Up 6.6%Here's Why - MarketBeat
ImmunityBio Stock Skyrockets Amid FDA Progress and Clinical Advances - StocksToTrade
MAHA Action Media Hub - ImmunityBio
Scrutiny Over FDA Communications Weighs on ImmunityBio Shares - AD HOC NEWS
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
Lilly, Repertoire strike $2 billion autoimmune alliance - statnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Brokers Offer Predictions for ImmunityBio FY2027 Earnings - MarketBeat
ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say - statnews.com
A High-Stakes Surge for ImmunityBio Shares - AD HOC NEWS
Positive Regulatory Developments and Stellar Growth for ImmunityBio - AD HOC NEWS
ImmunityBio Surges on Trial Success and Saudi FDA Approvals - timothysykes.com
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 6%Should You Sell? - MarketBeat
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run - Finviz
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Investing News Network
ImmunityBio Shares Pull Back Following Significant Advance - AD HOC NEWS
How Is The Market Feeling About ImmunityBio Inc? - Benzinga
Brokers Set Expectations for ImmunityBio FY2030 Earnings - MarketBeat
Is It Too Late To Reassess ImmunityBio (IBRX) After The Recent Oncology Headlines? - Yahoo Finance
ImmunityBio (NASDAQ:IBRX) Shares Gap DownHere's What Happened - MarketBeat
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - AOL.com
ImmunityBio, Inc. (IBRX) Stock Analysis: Potential Upside Of 90% For This Biotech Innovator - DirectorsTalk Interviews
ImmunityBio Stock Surge Backed by Strong Fundamentals - AD HOC NEWS
Undercovered Dozen: Incyte, Annaly Capital, ImmunityBio And More - Seeking Alpha
ImmunityBio Glioblastoma Data Add Fuel To Rapidly Moving IBRX Story - simplywall.st
Clinical Data Fuels Investor Enthusiasm for ImmunityBio - AD HOC NEWS
0.23%
1.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):